Estimating the Detection Limit of Spectrofluorometers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Estimating the Detection Limit of Spectrofluorometers

A new Certified Reference Material from Starna Scientific allows the ultimate sensitivity of high-performance spectrofluorometers to be estimated. Traditionally, this was tested using very dilute solutions of fluorophores such as Quinine Sulfate. Near the detection limit, however, concentrations are so low that sample preparation becomes difficult, and there is a real risk of contamination.

When excited by UV or visible radiation, water emits a Raman peak that can be readily identified.  Because very few photons are involved in Raman scattering, the signal levels are very low, comparable to those produced by very low analyte concentrations in normal fluorescence measurements. The intensity and signal-to-noise ratio of the Raman signal therefore indicate the ultimate detection limit of the spectrofluorometer.

The reference material is a permanently sealed UV quartz 10mm fluorometer cuvette containing ultra-high purity water, supplied with a Certificate of Validation and full instructions for use. The certificate shows typical Raman spectra measured on a reference spectrophotometer traceable to NIST primary references, and signal-to-noise ratios calculated at two different excitation wavelengths.

Starna Scientific is accredited to ISO Guide 34 and ISO 17025.  Subject to appropriate storage and use, all Starna Certified Reference Materials carry a lifetime guarantee.

Starna Scientific Ltd.
www.starna.com
sales@starna.com
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here